Global Enramycin Premix 麻豆原创 Research Report 2023

Publication ID:

PB501239862

Publication Date:

January 11, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Agriculture [2]

Industry & Manufacturing [3]

Description:

Enramycin premix is formulated with enramycin, rice bran oil and corn flour. This product is a gray or gray-brown powder with a special odor. It is fermented by actinomycetes and is an unsaturated fatty acid. Polypeptide antibiotics combined with more than a dozen amino acids. It has a strong inhibitory effect on Gram-positive bacteria, and it is not easy to develop drug resistance after long-term use. It can change the distribution of bacterial communities in the intestinal tract, is conducive to the digestion and absorption of feed nutrients, promotes animal growth and improves feed conversion rate, so it is recommended as a pharmaceutical feed additive by many countries in the world. Enramycin is not easily absorbed, so there are fewer drug residues in the body of livestock and poultry.
The global Enramycin Premix market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Enramycin Premix is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Enramycin Premix is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Enramycin Premix include Takeda, AdvaCare, Phiphar Healthcare, Boehringer Ingelheim, Eli Lilly and Company, Ravioza Biotech, Zhejiang Dayang Biology Technology, Bornsun Bioengineering and Shandong Shengli Bioengineering, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Enramycin Premix, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Enramycin Premix.
The Enramycin Premix market size, estimations, and forecasts are provided in terms of output/shipments (K MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Enramycin Premix market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Enramycin Premix manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Takeda
AdvaCare
Phiphar Healthcare
Boehringer Ingelheim
Eli Lilly and Company
Ravioza Biotech
Zhejiang Dayang Biology Technology
Bornsun Bioengineering
Shandong Shengli Bioengineering
Apeloa Pharmaceutical
Hvsen Biotechnology
Segment by Type
Contains Enramycin 4%
Contains Enramycin 8%
Segment by Application
Pig Fodder
Chicken Fodder
Others
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by type, by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Enramycin Premix manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Enramycin Premix by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Enramycin Premix in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Enramycin Premix 麻豆原创 Overview
1.1 Product Definition
1.2 Enramycin Premix Segment by Type
1.2.1 Global Enramycin Premix 麻豆原创 Value Growth Rate Analysis by Type 2022 VS 2029
1.2.2 Contains Enramycin 4%
1.2.3 Contains Enramycin 8%
1.3 Enramycin Premix Segment by Application
1.3.1 Global Enramycin Premix 麻豆原创 Value Growth Rate Analysis by Application: 2022 VS 2029
1.3.2 Pig Fodder
1.3.3 Chicken Fodder
1.3.4 Others
1.4 Global 麻豆原创 Growth Prospects
1.4.1 Global Enramycin Premix Production Value Estimates and Forecasts (2018-2029)
1.4.2 Global Enramycin Premix Production Capacity Estimates and Forecasts (2018-2029)
1.4.3 Global Enramycin Premix Production Estimates and Forecasts (2018-2029)
1.4.4 Global Enramycin Premix 麻豆原创 Average Price Estimates and Forecasts (2018-2029)
1.5 Assumptions and Limitations
2 麻豆原创 Competition by Manufacturers
2.1 Global Enramycin Premix Production 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Enramycin Premix Production Value 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Key Players of Enramycin Premix, Industry Ranking, 2021 VS 2022 VS 2023
2.4 Global Enramycin Premix 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.5 Global Enramycin Premix Average Price by Manufacturers (2018-2023)
2.6 Global Key Manufacturers of Enramycin Premix, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Enramycin Premix, Product Offered and Application
2.8 Global Key Manufacturers of Enramycin Premix, Date of Enter into This Industry
2.9 Enramycin Premix 麻豆原创 Competitive Situation and Trends
2.9.1 Enramycin Premix 麻豆原创 Concentration Rate
2.9.2 Global 5 and 10 Largest Enramycin Premix Players 麻豆原创 Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Enramycin Premix Production by Region
3.1 Global Enramycin Premix Production Value Estimates and Forecasts by Region: 2018 VS 2022 VS 2029
3.2 Global Enramycin Premix Production Value by Region (2018-2029)
3.2.1 Global Enramycin Premix Production Value 麻豆原创 Share by Region (2018-2023)
3.2.2 Global Forecasted Production Value of Enramycin Premix by Region (2024-2029)
3.3 Global Enramycin Premix Production Estimates and Forecasts by Region: 2018 VS 2022 VS 2029
3.4 Global Enramycin Premix Production by Region (2018-2029)
3.4.1 Global Enramycin Premix Production 麻豆原创 Share by Region (2018-2023)
3.4.2 Global Forecasted Production of Enramycin Premix by Region (2024-2029)
3.5 Global Enramycin Premix 麻豆原创 Price Analysis by Region (2018-2023)
3.6 Global Enramycin Premix Production and Value, Year-over-Year Growth
3.6.1 North America Enramycin Premix Production Value Estimates and Forecasts (2018-2029)
3.6.2 Europe Enramycin Premix Production Value Estimates and Forecasts (2018-2029)
3.6.3 China Enramycin Premix Production Value Estimates and Forecasts (2018-2029)
3.6.4 Japan Enramycin Premix Production Value Estimates and Forecasts (2018-2029)
4 Enramycin Premix Consumption by Region
4.1 Global Enramycin Premix Consumption Estimates and Forecasts by Region: 2018 VS 2022 VS 2029
4.2 Global Enramycin Premix Consumption by Region (2018-2029)
4.2.1 Global Enramycin Premix Consumption by Region (2018-2023)
4.2.2 Global Enramycin Premix Forecasted Consumption by Region (2024-2029)
4.3 North America
4.3.1 North America Enramycin Premix Consumption Growth Rate by Country: 2018 VS 2022 VS 2029
4.3.2 North America Enramycin Premix Consumption by Country (2018-2029)
4.3.3 United States
4.3.4 Canada
4.4 Europe
4.4.1 Europe Enramycin Premix Consumption Growth Rate by Country: 2018 VS 2022 VS 2029
4.4.2 Europe Enramycin Premix Consumption by Country (2018-2029)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Enramycin Premix Consumption Growth Rate by Region: 2018 VS 2022 VS 2029
4.5.2 Asia Pacific Enramycin Premix Consumption by Region (2018-2029)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Enramycin Premix Consumption Growth Rate by Country: 2018 VS 2022 VS 2029
4.6.2 Latin America, Middle East & Africa Enramycin Premix Consumption by Country (2018-2029)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
5 Segment by Type
5.1 Global Enramycin Premix Production by Type (2018-2029)
5.1.1 Global Enramycin Premix Production by Type (2018-2023)
5.1.2 Global Enramycin Premix Production by Type (2024-2029)
5.1.3 Global Enramycin Premix Production 麻豆原创 Share by Type (2018-2029)
5.2 Global Enramycin Premix Production Value by Type (2018-2029)
5.2.1 Global Enramycin Premix Production Value by Type (2018-2023)
5.2.2 Global Enramycin Premix Production Value by Type (2024-2029)
5.2.3 Global Enramycin Premix Production Value 麻豆原创 Share by Type (2018-2029)
5.3 Global Enramycin Premix Price by Type (2018-2029)
6 Segment by Application
6.1 Global Enramycin Premix Production by Application (2018-2029)
6.1.1 Global Enramycin Premix Production by Application (2018-2023)
6.1.2 Global Enramycin Premix Production by Application (2024-2029)
6.1.3 Global Enramycin Premix Production 麻豆原创 Share by Application (2018-2029)
6.2 Global Enramycin Premix Production Value by Application (2018-2029)
6.2.1 Global Enramycin Premix Production Value by Application (2018-2023)
6.2.2 Global Enramycin Premix Production Value by Application (2024-2029)
6.2.3 Global Enramycin Premix Production Value 麻豆原创 Share by Application (2018-2029)
6.3 Global Enramycin Premix Price by Application (2018-2029)
7 Key Companies Profiled
7.1 Takeda
7.1.1 Takeda Enramycin Premix Corporation Information
7.1.2 Takeda Enramycin Premix Product Portfolio
7.1.3 Takeda Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.1.4 Takeda Main Business and 麻豆原创s Served
7.1.5 Takeda Recent Developments/Updates
7.2 AdvaCare
7.2.1 AdvaCare Enramycin Premix Corporation Information
7.2.2 AdvaCare Enramycin Premix Product Portfolio
7.2.3 AdvaCare Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.2.4 AdvaCare Main Business and 麻豆原创s Served
7.2.5 AdvaCare Recent Developments/Updates
7.3 Phiphar Healthcare
7.3.1 Phiphar Healthcare Enramycin Premix Corporation Information
7.3.2 Phiphar Healthcare Enramycin Premix Product Portfolio
7.3.3 Phiphar Healthcare Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.3.4 Phiphar Healthcare Main Business and 麻豆原创s Served
7.3.5 Phiphar Healthcare Recent Developments/Updates
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Enramycin Premix Corporation Information
7.4.2 Boehringer Ingelheim Enramycin Premix Product Portfolio
7.4.3 Boehringer Ingelheim Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.4.4 Boehringer Ingelheim Main Business and 麻豆原创s Served
7.4.5 Boehringer Ingelheim Recent Developments/Updates
7.5 Eli Lilly and Company
7.5.1 Eli Lilly and Company Enramycin Premix Corporation Information
7.5.2 Eli Lilly and Company Enramycin Premix Product Portfolio
7.5.3 Eli Lilly and Company Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.5.4 Eli Lilly and Company Main Business and 麻豆原创s Served
7.5.5 Eli Lilly and Company Recent Developments/Updates
7.6 Ravioza Biotech
7.6.1 Ravioza Biotech Enramycin Premix Corporation Information
7.6.2 Ravioza Biotech Enramycin Premix Product Portfolio
7.6.3 Ravioza Biotech Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.6.4 Ravioza Biotech Main Business and 麻豆原创s Served
7.6.5 Ravioza Biotech Recent Developments/Updates
7.7 Zhejiang Dayang Biology Technology
7.7.1 Zhejiang Dayang Biology Technology Enramycin Premix Corporation Information
7.7.2 Zhejiang Dayang Biology Technology Enramycin Premix Product Portfolio
7.7.3 Zhejiang Dayang Biology Technology Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.7.4 Zhejiang Dayang Biology Technology Main Business and 麻豆原创s Served
7.7.5 Zhejiang Dayang Biology Technology Recent Developments/Updates
7.8 Bornsun Bioengineering
7.8.1 Bornsun Bioengineering Enramycin Premix Corporation Information
7.8.2 Bornsun Bioengineering Enramycin Premix Product Portfolio
7.8.3 Bornsun Bioengineering Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.8.4 Bornsun Bioengineering Main Business and 麻豆原创s Served
7.7.5 Bornsun Bioengineering Recent Developments/Updates
7.9 Shandong Shengli Bioengineering
7.9.1 Shandong Shengli Bioengineering Enramycin Premix Corporation Information
7.9.2 Shandong Shengli Bioengineering Enramycin Premix Product Portfolio
7.9.3 Shandong Shengli Bioengineering Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.9.4 Shandong Shengli Bioengineering Main Business and 麻豆原创s Served
7.9.5 Shandong Shengli Bioengineering Recent Developments/Updates
7.10 Apeloa Pharmaceutical
7.10.1 Apeloa Pharmaceutical Enramycin Premix Corporation Information
7.10.2 Apeloa Pharmaceutical Enramycin Premix Product Portfolio
7.10.3 Apeloa Pharmaceutical Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.10.4 Apeloa Pharmaceutical Main Business and 麻豆原创s Served
7.10.5 Apeloa Pharmaceutical Recent Developments/Updates
7.11 Hvsen Biotechnology
7.11.1 Hvsen Biotechnology Enramycin Premix Corporation Information
7.11.2 Hvsen Biotechnology Enramycin Premix Product Portfolio
7.11.3 Hvsen Biotechnology Enramycin Premix Production, Value, Price and Gross Margin (2018-2023)
7.11.4 Hvsen Biotechnology Main Business and 麻豆原创s Served
7.11.5 Hvsen Biotechnology Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Enramycin Premix Industry Chain Analysis
8.2 Enramycin Premix Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Enramycin Premix Production Mode & Process
8.4 Enramycin Premix Sales and 麻豆原创ing
8.4.1 Enramycin Premix Sales Channels
8.4.2 Enramycin Premix Distributors
8.5 Enramycin Premix Customers
9 Enramycin Premix 麻豆原创 Dynamics
9.1 Enramycin Premix Industry Trends
9.2 Enramycin Premix 麻豆原创 Drivers
9.3 Enramycin Premix 麻豆原创 Challenges
9.4 Enramycin Premix 麻豆原创 Restraints
10 Research Finding and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 麻豆原创 Size Estimation
11.1.3 麻豆原创 Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer

Companies Mentioned:

Takeda
AdvaCare
Phiphar Healthcare
Boehringer Ingelheim
Eli Lilly and Company
Ravioza Biotech
Zhejiang Dayang Biology Technology
Bornsun Bioengineering
Shandong Shengli Bioengineering
Apeloa Pharmaceutical
Hvsen Biotechnology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.